绥美凯治疗艾滋病疗效如何呢？

The recommended dosage of (Inbec) is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Dolutegra, as Trimax is a fixed-dose tablet and the dose cannot be reduced. If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. This once-a-day, one-tablet medication method significantly reduces the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life. Today we will learn about the effectiveness of Suimeikai in treating AIDS?

The effectiveness of TRIUMEQ in treating treatment-naïve HIV-infected subjects was based on data analysis from two randomized, international, double-blind, active-controlled trials, SINGLE (ING114467) and SPRING-2 (ING13086), and an international, open-label, active-controlled trial, FLAMINGO (ING114915). In SINGLE, 833 patients received dolutegravir 50 mg once daily plus fixed-dose abacavir-lamivudine (DTG-ABC/3TC) or fixed-dose efavirenz-tenofodoxine-emtricitabine (EFV/TDF/FTC). At baseline, the median age of patients was 35 years, 16% were female, 32% were nonwhite, 7% were co-infected with hepatitis C virus, and 4% were CDCC category. These characteristics were similar between the two treatment groups.

In the 48-week primary analysis, the proportion of patients achieving virological suppression was better in the dolutegravir XxXABC/3TC group than in the FTC/TDF/ETC group, p=0.003. The same treatment difference was observed among subjects defined by baseline HIV RNA levels (or 100,000 copies/ml). Median time to virological suppression was shorter in the ABC/3TCXxXDTG group (28 days vs. 84 days, p<0.0001). Relative to baseline, the adjusted mean changes in CD4 cell counts were 267 cells versus 208 cells/mm (p<0.001). Analyzes of time to attainment of virological suppression and change from baseline were prespecified and adjusted for multiplicity. At week 96, responses were 80% and -72%, respectively. The end point difference is still statistically significant (p=0.006). The statistically higher response in the DTGXxXABC/3TC group was primarily due to a higher proportion of withdrawals due to adverse events in the FTC/TDF/FTC group, independent of viral load stratification. Overall treatment differences at week 96 applied to patients with higher and lower baseline viral loads. Patients could maintain virological suppression during the 1440 weeks of the SINGLE open period, and the DTGXxXABC/3TC group (71%) was better than the EFV/TDF/FTC group (63%), with a treatment difference of 8.3% (2.0, 14.6). TRIUMEQ is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. It breaks the gap in the original single-pill compound preparation for the treatment of HIV in the market and brings treatment hope to more HIV patients.

The above is the content of the efficacy of AIDS treatment, I hope it can help you!